Pmda - Pharmaceuticals and Medical Devices Agency
Menu
Close

Post-marketing Safety Measures

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2025)

FY 2025 (No.418-)

Issue No. Table of contents
May 2025 419 Full text [507 KB]
  • Article 1. The Manuals for Management of Individual Serious Adverse Drug Reactions
  • Article 2. Revisions of PRECAUTIONS (No.359)
    Article 2.-1 Desmopressin acetate hydrate (and 3 others)
  • Article 3. List of Products Subject to Early Post-marketing Phase Vigilance
April 2025 418 Full text [684 KB]
  • Article 1. Efforts Against Abuse of Over-the-Counter Drugs
  • Article 2. Important Safety Information
    Article 2.-1 Dulaglutide (genetical recombination)
  • Article 3. Revisions of PRECAUTIONS (No.358)
    Article 3.-1 Dulaglutide (genetical recombination) (and 4 others)
  • Article 4. List of Products Subject to Early Post-marketing Phase Vigilance